Pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and application thereof

Abstract

The invention discloses a pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and application thereof and belongs to the field of biological vaccines. The pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen adopts a strategy of an antigenized antibody, after main antigen epitopes of a plurality of strains of pig foot-and-mouth disease virus O-type are connected in series reasonably, the plurality of strains of pig foot-and-mouth disease virus O-type are coupled with a pig intravenous gamma globulin (IgG) heavy chain constant region to construct the pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen, and after ration through a Bio-Rad protein ration kit, the pig foot-and-mouth disease virus O-type broad spectrum multi-epitope recombination antigen and recombination foot-and-mouth disease virus 3D protein are matched to prepare the vaccines. Animal immunity testing results show that the vaccines can stimulate an organism to generate high-titer protective antibodies when the vaccines are used independently or matched with the recombination foot-and-mouth disease virus 3D protein to be used, an antibody level is higher than a national standard, and good application prospects are achieved.

Description

technical field [0001] The invention relates to a porcine foot-and-mouth disease virus recombinant antigen and its application, in particular to a porcine foot-and-mouth disease virus O-type broad-spectrum multi-epitope recombinant antigen and its application, and also relates to a vaccine prepared from the antigen, which belongs to the field of biological vaccines. Background technique [0002] Foot-and-mouth disease, as a major animal disease that infects pigs, cattle and sheep as the main economic livestock, not only seriously threatens the healthy development of animal husbandry, but also involves the safety of animal-derived food and its foreign trade export. Once an epidemic occurs, the losses will be heavy and the impact will be severe. Inactivated vaccines, as the main prevention and control materials, play a very important role in the control of FMD epidemics. However, the production of such vaccines requires the construction of high-level biosafety production works...

AI Technical Summary

Problems solved by technology

However, the large-scale animal experiments all ended in failure (the protection rate of the virus attack did not reach the national standard), mainly because the small molecule antigens developed could not stimulate the body to produce a protective level of neutralizing antibodies, and some even could produce a certain level of protection. Antibodies, but the duration is short, which cannot meet the needs of epidemic prevention and control

In addition, the developed viral particle-like capsid protein can induce the body to produce high-titer protective antibodies, and immunized animals can resist the challenge of homologous viruses, but the low yield and high cost of the antigen limit the application of the vaccine

Recently, people have increased the immunogenicity of vaccines by increasing T cell epitopes and foreign carrier proteins to enhance antigen presentation capabilities, increase molecular weight, and promote B cell maturation and differentiation, enhance immune response, and increase the level of peripheral blood circulating antibodies and duration, although the immunogenicity of the antigen has been improved to a certain extent, the anti-foreign carrier protein antibody produced after multiple immunizations has affected the immune effect of the target antigen; in addition, because the T cell epitope used by the researchers It is not a universal epitope, that is, it cannot be recognized by the major histocompatibility complex (MHC-I and II) of all host animals, so it cannot induce immune responses in all animals

In recent years, the epitope vaccine constructed by coupling the main immune factors such as IFN-γ, IL-2, etc. to the epitope small molecule has become a new breakthrough in the research of epitope vaccine, but the immune effect on this animal is not ideal

[0004] At present, although the porcine foot-and-mouth disease virus O-type recombinant vaccine developed by Professor Zheng Zhaoxin of Fudan University in Shanghai has applied for a patent and obtained the "Class I New Veterinary Drug Certificate" issued by the Ministry of Agriculture, the product has not been commercialized due to various reasons

In my country, inactivated vaccines are still used in the prevention of O-type foot-and-mouth disease in pigs. The UBI synthetic peptide vaccine has a poor immune effect and the market prospect is bleak. The inventor has previously applied for patents for sheep and cattle Asia 1 type multi-epitope vaccines, which are currently under review

Images